Stryker (SYK) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Stryker

NYSE•Healthcare•Medical Devices

$306.81+14.95(0.05%)After hours

Market Cap

$117.26B

P/E

32.4x

P/S

4.5x

P/B

5.0x

Stryker Corporation operates as a medical technology company in the United States and internationally. It operates through two segments, MedSurg and Neurotechnology, and Orthopaedics. The MedSurg and Neurotechnology segment offers surgical equipment, patient and caregiver safety technologies, navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, clinical communication and artificial intelligence-assisted virtual care platform technology, and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke and venous thromboembolism; traditional brain and open skull based surgical procedures products; and orthobiologic and biosurgery products, including synthetic bone grafts and vertebral augmentation products. The Orthopaedics segment provides implants for use in total joint replacements, such as hip, knee and shoulder, ankle, and trauma and extremities surgeries; and Mako Shoulder, which expands the smart robotics suite of applications. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 61 countries. Stryker Corporation was founded in 1941 and is headquartered in Portage, Michigan.

How this company scores

ExcellentMetricSide Score: 81/100

Strongest: Cash & Earnings Quality (23/25); weakest: Balance Sheet & Red Flags (16/25).

Profitability22/25

Growth20/25

Balance Sheet & Red Flags16/25

Cash & Earnings Quality23/25

Strengths

Strong marginsHigh ROERising earningsCash-backed earnings

No red flags in the last 8 quarters.

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 32.4x5y range 31.6x – 51.8x

Currently near its 20-quarter median.

P/S · 4.5x5y range 4.3x – 6.4x

Currently near its 20-quarter median.

P/B · 5.0x5y range 4.7x – 7.1x

Price & Volume

Market Cap $117.26B

Metrics at a Glance

as of September 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $26.30B
Q. Revenue: $6.52B
TTM EBITDA: $7.04B
TTM Op. Income: $5.43B
Q. Op. Income: $1.03B
TTM Net Income: $3.62B
Q. Net Income: $753.00M
EPS: $1.97
Shares Out.: $382.20M

$26.30B in TTM revenue grew 7.9% YoY, reaching $6.52B last quarter. TTM EBITDA of $7.04B and TTM operating income of $5.43B show growth is flowing through to the bottom line. TTM net income of $3.62B means revenue is converting into profit. Across the last 8 quarters, TTM revenue has risen for 7 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 65.2%
EBITDA Margin: 21.9%
Op. Margin: 15.9%
Net Margin: 11.5%

Op. margin of 15.9% is down 2.9% YoY — costs are rising relative to revenue. Net margin at 11.5% and gross margin of 65.2% show how much of each revenue dollar survives to profit. Over the past year, operating margin is down 15% — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: 32.4x
P/S Ratio: 4.5x
P/B Ratio: 5.0x

At 32.4x P/E, the stock trades above typical market levels — the market expects above-average growth. P/S of 4.5x and P/B of 5.0x provide additional context. Use the growth and margin sections to judge whether the multiple is justified. Across the last 8 quarters, P/E has fallen for 5 consecutive quarters — an improving trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $47.25B
Cash: $3.27B
Long-Term Debt: $14.18B
Book Value: $23.46B
D/E Ratio: 0.6
Debt/EBITDA: 9.9

With $47.25B in assets and $14.18B in long-term debt, D/E is 0.6and book value is $23.46B — a conservative capital structure with a cushion to weather downturns. Over the past year, debt/equity is down 11% — a weakening trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $1.46B
TTM Free Cash Flow: $4.57B
FCF Margin: 17.4%
FCF / Net Income: 1.3

TTM FCF of $4.57B on $1.46B in operating cash flow. The FCF / Net Income ratio of 1.3x means free cash flow covers net income — earnings are backed by cash. Over the past year, free cash flow is up 12% — a weakening trend.